Immuneering Corp Balance Sheet
IMRX|3 years of annual SEC 10-K data (FY2021-FY2023)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 3 fiscal years. All figures from audited SEC 10-K filings.
Immuneering Corp had $103M in total assets and $110M in shareholders' equity as of FY2023.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Cash & Equivalents | $59.4M | $72.6M | $74.9M |
| Accounts Receivable | - | $12.4K | $246.0K |
| Current Assets | $89.1M | $108.7M | $152.3M |
| PP&E (Net) | $1.4M | $1.4M | $807.2K |
| Goodwill | $6.7M | $6.7M | $6.7M |
| Total Assets | $102.6M | $122.4M | $166.7M |
| Current Liabilities | $7.8M | $8.1M | $5.6M |
| Shareholders' Equity | $109.9M | $156.0M | -$22.5M |